Boston Scientific to buy Penumbra in $14.5 billion deal
Jan 15 (Reuters) - Boston Scientific said on Thursday it will buy Penumbra in a deal valued at about $14.5 billion to expand its vascular pipeline.
The deal values Penumbra at $374 per share, a premium of about 19.3% to its last close. Penumbra's shares rose over 10% in premarket trading, while Boston's shares fell 4%.
The transaction is expected to be completed in 2026.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shreya Biswas)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Is Aave (AAVE) Setting Up for a Potential Breakout Next Week? Key Emerging Pattern in Focus
Altcoin XRP Setting Up for the C Wave Push, Ripple’s Native Asset Prepares for Bullish Ascent
Sequoia to join GIC, Coatue in Anthropic investment, FT reports
Trending news
MoreCrypto prices
More
